Neogen Chemicals Board Approves Up To ₹600 Crore QIP Fundraising Plan

Q1 FY27 Consolidated Results YoY: Revenue at 250 Cr vs 187 Cr, up 34.0%. EBITDA at 52.3 Cr vs 32.7 Cr, up 59.7%. EBITDA Margin at 20.9% vs 17.5%, expansion of 340bps. PAT at 17.1 Cr vs 10.3 Cr, up 66.8%. Board approved raising up to Rs 600 Cr via QIP/other instruments, subject to shareholder approval. CRISIL downgrade to A-/Negative effective Jul 17, coupon on NCDs increased to 11% from 10.5%. Board of subsidiary Neogen Morita New Materials approved increase in borrowing powers to Rs 500 Cr.